{'fraction_non_alphanumeric': 0.02639019792648445, 'fraction_numerical': 0.010367577756833177, 'mean_word_length': 5.0685714285714285, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Multivesicular liposome formulations for the sustained delivery of interferon alpha-2b.

AIM
To develop and optimize a sustained release multivesicular liposome (MVL) formulation of interferon (IFN) alpha-2b.


METHODS
IFN alpha-2b MVL were prepared using a typical double-emulsion procedure. The sustained release effects of IFN alpha-2b MVL were investigated by monitoring the blood IFN alpha-2b concentration using an enzyme-linked immunosorbent assay test after subcutaneous administration to healthy mice.


RESULTS
IFN alpha-2b was successfully encapsulated in MVL with high efficiency, and the integrity of encapsulated protein was maintained. After subcutaneous injection, the MVL slowly released IFN alpha-2b into systemic circulation in a sustained manner. The estimated serum half-life of IFN alpha-2b was approximately 30 h. In addition, varying the size of the MVL preparations could further modify the in vivo release profile.


CONCLUSION
IFN alpha-2b MVL may be a useful sustained release formulation in the clinical treatment of viral diseases.